European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Gut-liver axis’ protein impact: Influence of dietary protein on gene expression and metabolic phenotype in the gut-liver axis

Final Report Summary - GLAPI (Gut-liver axis’ protein impact: Influence of dietary protein on gene expression and metabolic phenotype in the gut-liver axis)

High protein (HP) diets are suggested to positively modulate obesity and associated increased prevalence of non-alcoholic fatty liver (NAFLD) disease in humans as well as in rodents. The gut and the liver are the key organs in nutrient absorption and metabolism and therefore play a key role in the adaption to a HP diet. The gut adapts to the composition of the diet by direct substrate effects in addition to neural and endocrine mechanisms. These adaptations include the intestinal mucosa and the gut microbiota. Depending on the diet, the profile of nutrients, metabolites, gut peptides and other mediators released from the gut can be modified. The liver is the first organ which comes into contact with the molecules arising from gut digestion. Nutrients and metabolites delivered from the intestine are sensed in the liver and trigger an adaptation of liver function to improve their hepatic processing. These processes together with neural and endocrine mechanisms regulate liver function and exert a direct or indirect feedback control of gut function.
The objective of this project was to detect mechanisms by which a HP diet affects hepatic lipid accumulation and obesity. Moreover we aimed to study the effect of HP on the intestinal mucosa and the microbiota. Additionally, we linked the experiments in rodents to a clinical study that is currently performed in an accompanying project.
To investigate the acute and long term effect of high protein ingestion on hepatic lipid accumulation and body fat under both low and high fat (HF) conditions, mice were fed combinations of high (35 energy%) or low (10 energy%) fat and high (50energy%) or normal (15 energy%) protein diets for 1 or 12 weeks. The analyses include gene expression and metabolic phenotyping in the gut mucosa and liver, characterization of the microbiota, gut, liver and peripheral inflammatory state, hepatic lipogenesis and steatosis, body composition and food intake behavior.
Food intake was not affected by the different diets. However, mice fed the HP diets displayed a lower body weight, developed less adiposity and decreased hepatic lipid accumulation, which could be attributed to a combination of several processes. Next to an increased hepatic VLDL production rate, increased energy utilization due to enhanced protein catabolic processes, such as transamination, TCA cycle and oxidative phosphorylation was found upon high protein ingestion. Mostly comparable effects were observed in humans; effect sizes were however much more subtle. Analysis of the signalling effect of selected dietary amino acids on the liver are still on going.
With respect to the intestine, preliminary analysis of the small intestinal gene expression data also suggested enhanced protein catabolism, and suppression / delay of lipid uptake and metabolism. However, effects of increased dietary protein on gene expression were only modest compared to those of increased dietary fat. Moreover, the morphology, villus-length and crypt depth, and cell proliferation in the small intestine was not affected by increased dietary protein, in contrast to increased dietary fat. Analyses of the microbiome composition of the distal small intestine revealed no significant changes, despite an increased concentration of branched-chain short-chain fatty acids that are markers for increased protein fermentation.

Taken together, it was demonstrated that feeding a HP diet prevented the development of adiposity and NAFLD in mice by enhancing lipid secretion into VLDL particles and a less efficient use of ingested calories. Understanding the underlying molecular mechanisms of these effects will further contribute evidence-based dietary advice in the combat against obesity and the metabolic syndrome.